Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

CONTEXT Cancer genetics is fundamental for preventive medicine, in particular in pheochromocytoma-associated syndromes. Variants in two susceptibility genes, SDHC and RET, were found in a kindred with head and neck paraganglioma. This observation of coincident DNA variants, both reported as pathogenic, in two known susceptibility genes prompted the question of their pathogenic relevance. OBJECTIVE Our objective was to elucidate the pathogenic role of the detected variants and study the prevalence of such variants. PATIENTS Patients were registrants from the European-American Pheochromocytoma-Paraganglioma and German von Hippel-Lindau Disease Registries. DESIGN Analysis of germline mutation screening results for all pheochromocytoma-paraganglioma susceptibility genes, including RET [multiple endocrine neoplasia type 2 (MEN 2)] and VHL [von Hippel-Lindau disease (VHL)]. Cases in which more than one DNA variant was found were clinically reevaluated, and cosegregation of the disease with the variant was analyzed within the registrants' families. A total of 1000 controls were screened for the presence of detected variants, and in silico analyses were performed. RESULTS Three variants were identified, RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser. The frequencies of RET p.Ser649Leu (0.07%) and p.Tyr791Phe (0.9%) compared with controls excluded the two variants' role in the etiology of MEN 2 and VHL. None of the carriers of the RET variants who underwent prophylactic thyroidectomy showed medullary thyroid carcinoma. Clinical reinvestigation of 18 variant carriers excluded MEN 2. VHL variant p.Pro81Ser, also previously described as a mutation, did not segregate with the VHL in one family. In silico analyses for these variants predicted unmodified protein function. CONCLUSIONS RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser are definitely not pathogenic mutations for VHL and MEN 2. Misinterpretation results in irreversible clinical consequences.

[1]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[2]  H. Neumann,et al.  Familial pheochromocytoma , 2009, Hormones.

[3]  R. Krijger Early and precursor lesions in endocrine pathology: innocent lambs or wolves in sheep's clothing? , 2007 .

[4]  H. Buhr,et al.  Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. , 2006, European journal of endocrinology.

[5]  G. Heinze,et al.  Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. , 2004, Thyroid : official journal of the American Thyroid Association.

[6]  H. Dralle,et al.  Early malignant progression of hereditary medullary thyroid cancer. , 2003, The New England journal of medicine.

[7]  F. Raue,et al.  Hereditäres medulläres Schilddrüsenkarzinom - Genotyp - Phänotyp Charakterisierung1 , 2003 .

[8]  F. Raue,et al.  [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization]. , 2003, Deutsche Medizinische Wochenschrift.

[9]  H. Dralle,et al.  RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome? , 2002, Surgery.

[10]  W. Böcker,et al.  Surgical Strategy in a Kindred with a Rare RET Protooncogene Mutation of Variable Penetrance with Regard to Multiple Endocrine Neoplasia , 2002, World Journal of Surgery.

[11]  R. Hinze,et al.  Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. , 2002, Thyroid : official journal of the American Thyroid Association.

[12]  R. Tashjian,et al.  Germline RET 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[14]  M. Ivan,et al.  von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.

[15]  M. Wiench,et al.  Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Pasini,et al.  Frequency of RET mutations in long‐ and short‐segment Hirschsprung disease , 1997, Human mutation.

[17]  B. Ponder,et al.  Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. , 1995, JAMA.

[18]  J. Holst,et al.  C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  J. Tucci,et al.  C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto's thyroiditis. , 1989, The American journal of surgical pathology.

[20]  M. Nadji,et al.  C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. , 1988, Human pathology.

[21]  C. Fenoglio-Preiser,et al.  Endocrine changes associated with the human aging process: III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. , 1985, Human pathology.

[22]  B. Croker,et al.  C-cell nodules in adult human thyroid. A common autopsy finding. , 1981, American journal of clinical pathology.